Evidence map›Paper›PMID 41326648›Full record

ArticleBritish journal of cancer2026

Antigen-specific CD8

Konstantina Dimopoulou, Aris Spathis, Christina Papamichail, Aikaterini Athanasiadou, Abraham Pouliakis, Christakis Risilia, Despoina Myoteri, Panayiotis Kokoropoulos, Manousos Konstantoulakis, Ioannis G Panayiotides and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Konstantina DimopoulouDepartment of Gastroenterology, Red Cross Hospital, Athens, Greece.
Aris Spathis2nd Department of Pathology, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital, Athens, Greece.ORCID http://orcid.org/0000-0001-8867-3661
Christina Papamichail2nd Department of Pathology, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital, Athens, Greece.
Aikaterini Athanasiadou2nd Department of Pathology, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital, Athens, Greece.
Abraham Pouliakis2nd Department of Pathology, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital, Athens, Greece.ORCID http://orcid.org/0000-0002-0074-3619
Christakis Risilia2nd Department of Pathology, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital, Athens, Greece.
Despoina MyoteriDepartment of Pathology, National and Kapodistrian University of Athens, Medical School, Aretaieion Hospital, Athens, Greece.
Panayiotis Kokoropoulos4th Department of Surgery, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital, Athens, Greece.
Manousos Konstantoulakis2nd Department of Surgery, National and Kapodistrian University of Athens, Medical School, Aretaieion Hospital, Athens, Greece.
Ioannis G Panayiotides2nd Department of Pathology, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital, Athens, Greece.
Nikolaos Arkadopoulos4th Department of Surgery, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital, Athens, Greece.
Dina TiniakosDepartment of Pathology, National and Kapodistrian University of Athens, Medical School, Aretaieion Hospital, Athens, Greece.
Periklis G Foukas2nd Department of Pathology, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital, Athens, Greece. pfoukas@med.uoa.gr.ORCID http://orcid.org/0000-0002-6053-7841

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTumour antigen-specific CD8

methodsWe analyzed 100 HCC patients undergoing curative hepatectomy. Multiplex immunohistochemistry (CD8/CD39/TCF1, CD8/CD39/TOX) was applied on tissue microarray sections with digital imaging used to evaluate T cell infiltration in tumour center, periphery and adjacent non-neoplastic liver. Tertiary lymphoid structures (TLS) were assessed on H&E-stained slides.

resultsIn HCC TME, 72% of CD8

conclusionsPatients with HCC and high CD8

Indexed as

ApyraseCarcinoma, HepatocellularCD8-Positive T-LymphocytesLiver NeoplasmsT-Lymphocytes, CytotoxicTumor MicroenvironmentAdultAgedFemaleHepatocyte Nuclear Factor 1-alphaHigh Mobility Group ProteinsHumansLymphocytes, Tumor-InfiltratingMaleMiddle AgedPrognosisApyraseENTPD1 protein, humanHepatocyte Nuclear Factor 1-alphaHigh Mobility Group ProteinsHNF1A protein, humanTOX protein, human

Identifiers

PMID41326648
PMCPMC12852811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.